Toriola AT, Luo S, Thomas TS, et al. - Researchers sought to assess how metformin use influences the survival of patients with pancreatic ductal adenocarcinoma (PDAC). From the United States Veterans Health Administration, they assessed data of 3,811 PDAC patients with pre-existing diabetes mellitus (DM). The analysis revealed no links between metformin use and survival in PDAC patients. However, non-Hispanic white patients who were metformin naïve at the time of PDAC diagnosis seemed to have a survival benefit.